Impact of Drug Detailing for Gabapentin
Author Information
Author(s): Steinman Michael A, Harper G. Michael, Chren Mary-Margaret, Landefeld C. Seth, Bero Lisa A
Primary Institution: San Francisco Veterans Affairs Medical Center
Hypothesis
What is the content and impact of detail visits for gabapentin on prescribing behavior?
Conclusion
Detail visits for gabapentin were perceived as highly informative and often promoted unapproved uses, leading many physicians to intend to increase their prescribing of the drug.
Supporting Evidence
- 46% of physicians intended to increase their prescribing of gabapentin after detail visits.
- 38% of visits included messages about unapproved uses of gabapentin.
- Most detail visits were rated highly for informational value.
Takeaway
When drug representatives visit doctors to talk about gabapentin, many doctors decide they want to prescribe it more, even if the drug is not approved for all the uses mentioned.
Methodology
The study analyzed market research forms completed by physicians after detail visits for gabapentin.
Potential Biases
Physicians may have tailored their responses to be more socially acceptable due to the nature of the survey.
Limitations
The study relied on self-reported data, which may be subject to bias, and the sample was limited to a specific time period.
Participant Demographics
The sample included 97 physicians from various specialties, with a majority being non-neurologists.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website